Get the Stockscreener App
0.2351
0.17%
-0.0004
Pre-market:
.23
-0.0051
-2.17%
Jupiter Neurosciences Inc stock is traded at $0.2351, with a volume of 1.40M.
It is down -0.17% in the last 24 hours and down -30.44% over the past month.
Jupiter Neurosciences Inc is a clinical-stage research and development company focused on developing treatments for neuroinflammation through the resveratrol platform. Its platform product, JOTROL, is an enhanced oral formulation of resveratrol, which has many potential indications. In the larger disease areas, which are targeting Parkinson's Disease. The group is presently in the process of conducting a Phase IIa clinical trial in Parkinson's Disease. The company operates through two reportable segments: premium nutritional supplements and pharmaceutical operations focused on drug candidates for CNS and rare orphan diseases. It generates the majority of its revenue from Premium Nutritional Supplements, which includes commercialization and sales of the Company's Nugevia product line.
See More
Previous Close:
$0.2355
Open:
$0.236
24h Volume:
1.40M
Relative Volume:
0.25
Market Cap:
$10.21M
Revenue:
$40,400
Net Income/Loss:
$-9.18M
P/E Ratio:
-0.8759
EPS:
-0.2684
Net Cash Flow:
$-5.78M
1W Performance:
+1.42%
1M Performance:
-30.44%
6M Performance:
-79.56%
1Y Performance:
-74.99%
1-Day Range:
$0.234
$0.2476
1-Week Range:
$0.2141
$0.254
52-Week Range:
$0.1721
$3.33
Jupiter Neurosciences Inc Stock (JUNS) Company Profile
Name
Jupiter Neurosciences Inc
Sector
Industry
Phone
(561) 406-6154
Address
1001 NORTH US HWY 1, JUPITER
Compare JUNS vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
JUNS
Jupiter Neurosciences Inc
|
0.2351 | 10.23M | 40,400 | -9.18M | -5.78M | -0.2684 |
VRTX
Vertex Pharmaceuticals Inc
|
453.17 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.73 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
878.49 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
281.90 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
156.58 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Jupiter Neurosciences Inc Stock (JUNS) Latest News
Reunion Neuroscience Announces Appointment of Sahil V. Kirpekar, M.D., as President and CEO - Yahoo Finance
Jupiter Neurosciences Inc. (JUNS) Q4 2025 Earnings: Narrower-than-expected loss highlights clinical pipeline progress - newsline.com
A Tiny Psychedelic Stock Just Exploded Over 50% – Retail Traders Think $1 Is Next - Stocktwits
JUNS Q4 2025 Earnings: Narrower Loss Per Share Surpasses Estimates Amid No Revenue - newsline.com
JUNS stock sees best single-day gains in almost a year on $100M MDMA drug licensing deal – retail expects shares to hit $1 - MSN
Jupiter stock soars after $100 million ALA-002 licensing deal - MSN
Jupiter Neurosciences (JUNS) proposes 5.25M-plan increase and 1:10–1:100 reverse split - Stock Titan
Jupiter Neurosciences regains Nasdaq compliance for minimum share price - MSN
JUNS SEC FilingsJUPITER NEUROSCIENCES, INC. 10-K, 10-Q, 8-K Forms - Stock Titan
Jupiter Neurosciences, Inc. Announces Amendment No. 3 to Executive Employment Agreement for Alison Silva – SEC 8-K Filing, Nasdaq Listed Emerging Growth Company 14151618 - Minichart
Jupiter Neurosciences Promotes Silva to COO and President - TipRanks
Jupiter Neurosciences appoints Alison Silva as COO and President, grants options to executives - TradingView
Jupiter Neurosciences Inc. (JUNS) Q4 2025 Earnings: Narrower Loss Beats Expectations, but Stock SlipsRevenue Warning Signal - newsline.com
Jupiter Neurosciences (JUNS) Slides 11.57% as Selling Pressure Tests Key Support Near $0.25Risk Reversal - newsline.com
Jupiter Neurosciences (JUNS) Plunges 11.6%, Testing Key Support at $0.25Factor Timing - The Legal Advocate
D. Boral Capital Acted as Exclusive Placement Agent to Jupiter Neurosciences, Inc. (Nasdaq:JUNS) in Connection with its ~$2 Million Registered Direct Offering - ACCESS Newswire
Jupiter Neurosciences (JUNS) Slips 11.57%: Testing Key Support at $0.25Reversal Setup Alerts - newsline.com
12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga
Jupiter Neurosciences (JUNS) Gains 10% as Trading Volume Picks Up Near Key ResistanceConversion Trade - The Legal Advocate
Jupiter Neurosciences Jumps 13.5% as Speculative Interest Builds in Small-Cap BiotechIchimoku TK Cross - newsline.com
Jupiter Neurosciences Initiates Phase 2a RESET Trial Enrolling Parkinson’s Patients - geneonline.com
Jupiter Neurosciences says patient enrollment underway in phase 2a reset trial in Parkinson's disease - marketscreener.com
Jupiter Neurosciences Says Patient Enrollment Underway In Phase 2A Reset Trial In Parkinson's Disease - TradingView
Jupiter Neurosciences, Inc. Initiates Patient Enrollment for Phase 2a RESET Trial of JOTROL™ in Parkinson’s Disease - Quiver Quantitative
Jupiter Neurosciences Announces Patient Enrollment Underway in Phase 2a RESET Trial in Parkinson’s Disease - GlobeNewswire
Jupiter Neurosciences earnings missed, revenue fell short of estimates By Investing.com - Investing.com Canada
Jupiter Neurosciences earnings missed, revenue fell short of estimates - Investing.com
Jupiter Neurosciences Inc. (JUNS) Extends Slide – Key Support Levels Under PressureSector ETF Flow - thelegaladvocate.com
Jupiter Neurosciences (JUNS) Slips 3.28% as Shares Test Critical Support at $0.22Put Call Ratio - newsline.com
JUNS Q4 2025 Earnings: Narrower Loss Surprises, Yet Stock Falls on Pre‑Revenue PathPopular Market Picks - Newser
Jupiter Neurosciences (JUNS) Q4 2025 Earnings: EPS Beat Masks Zero-Revenue Reality; Shares Slide 12%Free Signal Network - Newser
What is Driving Jupiter Neurosciences' Recent Stock Volatility - Kavout
JUNS Q4 2025 Earnings: Narrower-Than-Expected Loss Reflects Cost Control Efforts Despite No RevenuePerformance Review - The Legal Advocate
Jupiter Neurosciences, Inc. Secures $2 Million in Direct Offering to Support Parkinson’s Program and Strengthen Balance Sheet - Quiver Quantitative
Jupiter Neurosciences Announces Closing of $2.0 Million Registered Direct Offering - marketscreener.com
What's going on in today's after hours session - ChartMill
Jupiter Neurosciences (JUNS) priced 7.14M-share direct offering at $0.28 - Stock Titan
The trading volume of these stocks is deviating from the norm in today's session. - ChartMill
Jupiter Neurosciences Announces Registered Direct Equity Offering - TipRanks
Jupiter Neurosciences (NASDAQ: JUNS) files May 21, 2026 prospectus supplement - Stock Titan
Jupiter Neurosciences Prices $2.0 Million Registered Direct Offering at $0.28 Per Share - TradingView
Jupiter Neurosciences (JUNS) raises $2.0M in registered direct stock sale - Stock Titan
Jupiter Neurosciences (JUNS) raises $2.0M via 7.14M-share placement - Stock Titan
JUNS Q4 2025 Earnings: Narrowed Loss Beats Estimates as Development Focus IntensifiesDividend Earnings Report - newsline.com
Jupiter Neurosciences Stock Swings on $100M MDMA Pact, $2M Equity Sale - TechStock²
Jupiter Neurosciences Secures $100M Term Sheet for U.S. Rights to PharmAla’s MDMA Therapy ALA-002 - The National Law Review
12 Health Care Stocks Moving In Wednesday's After-Market Session - Benzinga
Jupiter Neurosciences Inc Stock (JUNS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Jupiter Neurosciences Inc Stock (JUNS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| ROSEN CHRISTER | CEO and Chairman |
Jul 01 '25 |
Buy |
1.02 |
3,600 |
3,667 |
11,078,892 |
| Silva Alison D. | Pres + Chief Business Officer |
Jun 30 '25 |
Buy |
1.03 |
950 |
978 |
112,027 |
| Silva Alison D. | Pres + Chief Business Officer |
Jun 27 '25 |
Buy |
1.03 |
850 |
877 |
111,077 |
| ROSEN CHRISTER | CEO and Chairman |
Jun 30 '25 |
Buy |
1.02 |
7,650 |
7,810 |
11,075,292 |
| ROSEN CHRISTER | CEO and Chairman |
Jun 27 '25 |
Buy |
1.06 |
166 |
176 |
11,067,642 |
1.27%
1.43%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):